Research ReportsOrchid Pharma Q1 Results Review - Revenue Growth Outperforms Expectations, Margins Come In Weaker: Systematix
ADVERTISEMENT
Orchid Pharma Q1 Results Review - Revenue Growth Outperforms Expectations, Margins Come In Weaker: Systematix
The brokerage tweaks its forecasts and raises target valuation multiple to 50 times and recommend a Buy rating on the stock with a target price of Rs 1641.
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.